Work

Figure S5 from Targeting Semaphorin 7a Signaling in Preclinical Models of Endocrine Therapy–Resistant Breast Cancer

Year: 2026

Type: other

Abstract: Figure S5 shows in vitro and in vivo efficacy of the anti-SEMA7A antibody, SmAbH1, as well as the effect of SmAbH1 on pAKT, integrins B1 and B4, SEMA7A and ER.

DOI: 10.1158/1535-7163.33414246

Authors: Rachel N. Steinmetz, Veronica Wessells, Heather Fairchild, Virgina F. Borges, Traci R. Lyons

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7205007710

Cites:

Cited by:

Related to: